Immunotherapy [NEW TOPIC PAGE]

Main|Search|PHGKB




Last Posted: Sep 03, 2019

---

• Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
  S Ghorashian et al, Nature Medicine, September 2, 2019
• Study Tests Immunotherapy in People with Cancer and Autoimmune Diseases 
  NCI, August 26, 2019
• Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden
  D Bomze et al, JAMA Oncology, August 22, 2019
• Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1
  JS Lee et al, JAMA Oncology, August 22, 2019
• Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD-L1 immunotherapy.
  Wu Chih-Hsun et al. Cancer medicine 2019 Aug
• The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma.
  Chen Hao et al. Oncoimmunology 2019 8(8) 1608132
• Tumor mutation burden: from comprehensive mutational screening to the clinic.
  Galuppini Francesca et al. Cancer cell international 2019 19209
• Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.
  Wang Feng et al. JAMA oncology 2019 Aug
• Biology of nonmuscle-invasive bladder cancer: pathology, genomic implications, and immunology.
  Dyrskjøt Lars et al. Current opinion in urology 2018 28(6) 598-603
• Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'.
  Wu Hao-Xiang et al. Journal for immunotherapy of cancer 2019 Aug 7(1) 206

more